Parallax Volatility Advisers, L.P. Summit Therapeutics Inc. Transaction History
Parallax Volatility Advisers, L.P.
- $35.7 Billion
- Q1 2025
A detailed history of Parallax Volatility Advisers, L.P. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Parallax Volatility Advisers, L.P. holds 10,000 shares of SMMT stock, worth $270,700. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 5,547
80.28%
Holding current value
$270,700
Previous $99,000
93.94%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
244Shares Held
87.4MCall Options Held
1.77MPut Options Held
2.48M-
Baker Bros. Advisors LP New York, NY24.4MShares$661 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$315 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$214 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$178 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$131 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.45B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...